Type 1 Diabetes Mellitus Research and Development Services

Type 1 Diabetes Mellitus (T1DM) is an autoimmune disease, which may be caused by genes or the autoimmune system.

As a dedicated CRO company, Ace Therapeutics offers a full range of services related to T1DM, in order to help you make progress on the discovery of new or modified medications, insulin alternatives or treatments.

Pathogenesis of T1DM

T1DM occurs as a consequence of a breakdown in immune regulation, resulting in the expansion of autoreactive CD4⁺ and CD8⁺ T cells, autoantibody-producing B lymphocytes, and activation of the innate immune system that collaborate to destroy the insulin-producing β-cells.

Genetics of T1DM
About half of the heritability of T1DM is due to variations in three HLA class II genes involved in antigen presentation: HLA-DRB1, HLA-DQA1, and HLA-DQB1. However, genome-wide association studies (GWAS) have identified over 60 additional non-HLA loci associated with the risk of T1DM. These variants have been predominantly associated with the immune system and emphasize pathways that are important in disease development.

Pathogenesis of T1DM (Desai, S., et al., 2021)

Therapy Development of T1DM

The discovery of insulin makes T1DM no longer an incurable disease and greatly improves the life expectancy and quality of life of T1DM patients.

Our Services

Diabetes is a field worthy of in-depth research, and experts and scholars in the field of diabetes have never stopped pursuing technological innovation. Ace Therapeutics provides research programs and technical services from pathology to preclinical.

T1DM Pathology Research Service

Providing research services to study the genes, biochemical pathways related to diabetes at the molecular and cellular levels, and carry out integration and systematic analysis, which is helpful for the development of therapies.

T1DM Modeling Service

Providing modeling service for T1DM study for understanding the mechanism and development of T1DM, as well as developing therapy and diagnosis for T1DM.

T1DM Biomarker Development Service

Providing a set of services including metabolomics-based biomarker development, β-cell stress and death biomarkers development and gut microbiota-based biomarker development.

T1DM Diagnostic Development Service

We provide effective diagnostics development service based on different types of markers, that can help clients complete their disease model analysis more efficiently and help accelerate therapy development of T1DM.

Features of Our Services

Highly Customizable

One-stop Services

High Qualitys High Quality

Professional Team

With many years of experience in translational medicine research and drug development, Ace Therapeutics can provide partners with treatment development solutions, and accelerate the process of treatment development and drug discovery. We guarantee to deliver our products and results on time. Please feel free to contact us.

References

Inoue, R.; et al. The feasibility and applicability of stem cell therapy for the cure of type 1 diabetes. Cells. 2021, 10(7), 1589.
Desai, S., et al. (2021). Vaccines For Type 1 Diabetes: Prevention or Reversal?. Current diabetes reviews, 17(1), 30–36.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Services